Media coverage about Cytori Therapeutics (NASDAQ:CYTX) has been trending somewhat positive this week, according to Accern. Accern rates the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cytori Therapeutics earned a coverage optimism score of 0.12 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 45.0180932067096 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
CYTX has been the topic of several analyst reports. Maxim Group set a $5.00 target price on Cytori Therapeutics and gave the company a “buy” rating in a research report on Monday, November 13th. Zacks Investment Research cut Cytori Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, November 9th. Finally, B. Riley restated a “hold” rating on shares of Cytori Therapeutics in a research report on Tuesday, November 7th.
Shares of Cytori Therapeutics (CYTX) traded up $0.01 during mid-day trading on Thursday, hitting $0.26. The stock had a trading volume of 302,100 shares, compared to its average volume of 775,096. Cytori Therapeutics has a one year low of $0.22 and a one year high of $2.13.
About Cytori Therapeutics
Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.
What are top analysts saying about Cytori Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cytori Therapeutics and related companies.